董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Ulf Wiinberg | 男 | Director | 67 | 14.79万美元 | 7.31 | 2025-12-29 |
| Jennifer S. Buell | 女 | Director,Chief Executive Officer and President | 50 | 208.79万美元 | 42.17 | 2025-12-29 |
| Barbara Ryan | 女 | Director | 63 | 16.29万美元 | 3.61 | 2025-12-29 |
| Peter Behner | 男 | Director | 62 | 15.69万美元 | 3.33 | 2025-12-29 |
| John Holcomb | -- | Director | -- | 6.45万美元 | 0.11 | 2025-12-29 |
| Garo H. Armen | 男 | Co-Founder and Chairman | 73 | 0.15万美元 | 35.14 | 2025-12-29 |
| Brian Corvese | 男 | Director | 68 | 16.34万美元 | 9.92 | 2025-12-29 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jennifer S. Buell | 女 | Director,Chief Executive Officer and President | 50 | 208.79万美元 | 42.17 | 2025-12-29 |
| Christine M. Klaskin | 女 | Treasurer,Principal Financial Officer and Principal Accounting Officer | 59 | 2.98万美元 | 未持股 | 2025-12-29 |
董事简历
中英对照 | 中文 | 英文- Ulf Wiinberg
-
Ulf Wiinberg目前担任临床前疫苗研究公司X-VAX Technology，Inc.的首席执行官。在加入X-Vax之前，Wiinberg先生于2008年6月至2014年12月担任H.Lundbeck A/S（“；Lundbeck”；）的首席执行官。Lundbeck公司是一家全球制药公司，开发和营销治疗精神和神经疾病的药物。他此前曾任职于多个医疗保健行业协会的董事会，并担任Wyeth公司（世界上最大的研究驱动型制药公司之一，于2009年被Pfizer公司收购）的多种执行职务。他曾担任惠氏欧洲、非洲和中东地区总裁；消费者梦百合总裁；惠氏英国公司董事总经理，并担任多个商业职位。Wiinberg先生目前任职于总部位于比利时的全球生物制药公司UCB SA，瑞典生物制药公司Hansa Medical AB（主席）和瑞典工业公司Alfa Laval AB的董事会。
Ulf Wiinberg,has almost 20 years of senior leadership experience, most recently serving as Chief Executive Officer of X+Vax Technology A.S., a biotech company committed to developing vaccines against pathogens acquired by mucosal infection such as herpes. Mr. Wiinberg previously served as Chief Executive Officer of H. Lundbeck A/S ("Lundbeck") from June 2008 to December 2014. Lundbeck is a global pharmaceutical company developing and marketing treatments for psychiatric and neurological disorders. He previously served on the boards of several health care industry associations and held multiple executive roles at Wyeth, one of the world's largest research- driven pharmaceutical companies, when was acquired by Pfizer in 2009. He served as President of Wyeth Europe, Africa and Middle East; President of Consumer Healthcare; Managing Director of Wyeth UK, and in various commercial positions. Mr. Wiinberg currently serves on the boards of UCB SA, a global biopharmaceutical company based in Belgium, Hansa Medical AB (Chairman), a Swedish biopharmaceutical company, Alfa Laval AB, a Swedish industrial company, and Agenus. - Ulf Wiinberg目前担任临床前疫苗研究公司X-VAX Technology，Inc.的首席执行官。在加入X-Vax之前，Wiinberg先生于2008年6月至2014年12月担任H.Lundbeck A/S（“；Lundbeck”；）的首席执行官。Lundbeck公司是一家全球制药公司，开发和营销治疗精神和神经疾病的药物。他此前曾任职于多个医疗保健行业协会的董事会，并担任Wyeth公司（世界上最大的研究驱动型制药公司之一，于2009年被Pfizer公司收购）的多种执行职务。他曾担任惠氏欧洲、非洲和中东地区总裁；消费者梦百合总裁；惠氏英国公司董事总经理，并担任多个商业职位。Wiinberg先生目前任职于总部位于比利时的全球生物制药公司UCB SA，瑞典生物制药公司Hansa Medical AB（主席）和瑞典工业公司Alfa Laval AB的董事会。
- Ulf Wiinberg,has almost 20 years of senior leadership experience, most recently serving as Chief Executive Officer of X+Vax Technology A.S., a biotech company committed to developing vaccines against pathogens acquired by mucosal infection such as herpes. Mr. Wiinberg previously served as Chief Executive Officer of H. Lundbeck A/S ("Lundbeck") from June 2008 to December 2014. Lundbeck is a global pharmaceutical company developing and marketing treatments for psychiatric and neurological disorders. He previously served on the boards of several health care industry associations and held multiple executive roles at Wyeth, one of the world's largest research- driven pharmaceutical companies, when was acquired by Pfizer in 2009. He served as President of Wyeth Europe, Africa and Middle East; President of Consumer Healthcare; Managing Director of Wyeth UK, and in various commercial positions. Mr. Wiinberg currently serves on the boards of UCB SA, a global biopharmaceutical company based in Belgium, Hansa Medical AB (Chairman), a Swedish biopharmaceutical company, Alfa Laval AB, a Swedish industrial company, and Agenus.
- Jennifer S. Buell
-
Jennifer S.Buell自2018年以来一直担任我们的首席运营官，并于2019年12月成为我们的总裁。2013年11月至2016年7月，Buell博士担任该公司的Vice President、研究与开发运营和项目管理。2016年7月至2017年11月，她担任公司Vice President、研究和对外事务，2017年11月至2018年11月，她担任首席通信和对外事务官。Buell博士在塔夫茨大学（Tufts University）获得细胞、生化和分子生物化学博士学位，并获得生物统计学硕士学位。
Jennifer S. Buell,has been President and CEO of MiNK Therapeutics, Inc. (subsidiary of Agenus) and since 2023 the Chairman, Executive Council at Agenus. From 2018 to 2021, Dr. Buell was President and Chief Operating Officer at Agenus, where she was responsible for organizational operations, investor relations and external affairs. Prior to Agenus, Dr. Buell held leadership positions in R&D operations at Bristol-Myers Squibb and Harvard Clinical Research Institute (Baim), where she was involved in the development strategy and operations for a portfolio of industry and government-sponsored clinical programs. She obtained her Ph.D. in Cellular, Biochemical, and Molecular Biochemistry with an M.S. in Biostatistics from Tufts University. - Jennifer S.Buell自2018年以来一直担任我们的首席运营官，并于2019年12月成为我们的总裁。2013年11月至2016年7月，Buell博士担任该公司的Vice President、研究与开发运营和项目管理。2016年7月至2017年11月，她担任公司Vice President、研究和对外事务，2017年11月至2018年11月，她担任首席通信和对外事务官。Buell博士在塔夫茨大学（Tufts University）获得细胞、生化和分子生物化学博士学位，并获得生物统计学硕士学位。
- Jennifer S. Buell,has been President and CEO of MiNK Therapeutics, Inc. (subsidiary of Agenus) and since 2023 the Chairman, Executive Council at Agenus. From 2018 to 2021, Dr. Buell was President and Chief Operating Officer at Agenus, where she was responsible for organizational operations, investor relations and external affairs. Prior to Agenus, Dr. Buell held leadership positions in R&D operations at Bristol-Myers Squibb and Harvard Clinical Research Institute (Baim), where she was involved in the development strategy and operations for a portfolio of industry and government-sponsored clinical programs. She obtained her Ph.D. in Cellular, Biochemical, and Molecular Biochemistry with an M.S. in Biostatistics from Tufts University.
- Barbara Ryan
-
Barbara Ryan自2020年9月起担任Invo Fertility，Inc.董事会成员、审计委员会以及提名和治理委员会成员，自2024年5月起担任薪酬委员会主席。Ryan女士于2012年创立了资本市场和传播公司Barbara Ryan Advisors，此前她在华尔街担任了30多年的卖方研究分析师，覆盖美国大盘制药行业。Ryan女士在广泛的生命科学公司的股权和债务融资、并购、估值、SEC报告、财务分析和公司战略方面拥有丰富的经验。Ryan女士参与了几笔业内最大的并购交易；Shire对艾伯维恶意收购企图的辩护、Shire对Baxalta的收购、Allergan对Valeant的辩护以及培瑞克对Mylan的辩护。Ryan女士于2014年1月至2017年12月期间担任Radius Health的执行团队成员和披露委员会成员，在该公司的首次公开募股和随后的后续发行中发挥了关键作用，该公司筹集了超过10亿美元。此前，Ryan女士曾在德意志银行/Alex Brown担任董事总经理并担任该公司医药研究团队负责人长达19年，并于1982年在贝尔斯登开始了她覆盖医药行业的研究生涯。Ryan女士还覆盖了药物批发商和PBM，并且是包括Express Scripts、PSSI和亨利香恩服务在内的许多备受瞩目的IPO的首席分析师。Ryan女士目前在Indivior Pharmaceuticals，Inc.担任董事会董事，她在该公司担任薪酬委员会主席，在MiNK Therapeutics Therapeutics，她在该公司担任审计委员会主席，Safecor Health和Azitra Inc.以及非营利组织Red Door Community（前身为Gilda's Club NYC）担任董事会董事。Ryan女士是Fabulous Pharma Females的创始人，这是一家非营利组织，其使命是在生物制药行业推动女性发展，是《制药高管》杂志编辑顾问委员会成员，也是GLG研究所的教员。
Barbara Ryan has been a member of Invo Fertility, Inc.'s Board, a member of the Audit Committee and Nominating and Governance Committee since September 2020 and the Chairwoman of the Compensation Committee since May 2024. Ms. Ryan founded Barbara Ryan Advisors, a capital markets and communications firm, in 2012 following a more than 30 year career on Wall Street as a sell side research analyst covering the US Large Cap Pharmaceutical Industry. Ms. Ryan has deep experience in equity and debt financings, M&A, valuation, SEC reporting, financial analysis and corporate strategy across a broad range of life sciences companies. Ms. Ryan worked on several of the industry's largest M&A transactions; Shire's defense versus a hostile takeover attempt by Abbvie, Shire's takeover of Baxalta, Allergan's defense against Valeant and Perrigo's defense versus Mylan. Ms. Ryan served as an executive team member and on the disclosure committee for Radius Health from January 2014 to December 2017 and played a critical role in the company's IPO and subsequent follow on offerings which raised over $1 billion. Previously, Ms. Ryan was a Managing Director at Deutsche Bank/Alex Brown and Head of the company's Pharmaceutical Research Team for 19 years and began her research career covering the pharmaceutical industry at Bear Stearns in 1982. Ms. Ryan also covered the drug wholesalers and PBMs and was the lead analyst on many high profile IPO's including Express Scripts, PSSI, and Henry Schein. Ms. Ryan currently serves as a director on the Board of Indivior Pharmaceuticals, Inc. where she Chairs the Compensation Committee, MiNK Therapeutics where she Chairs the Audit Committee, Safecor Health, and Azitra Inc. as well as The Red Door Community (formerly Gilda's Club NYC), a non profit organization. Ms. Ryan is the Founder of Fabulous Pharma Females, a non profit whose mission is to advance women in the biopharma industry, is a member of the Editorial Advisory Board of Pharmaceutical Executive Magazine, and a Faculty member of the GLG Institute. - Barbara Ryan自2020年9月起担任Invo Fertility，Inc.董事会成员、审计委员会以及提名和治理委员会成员，自2024年5月起担任薪酬委员会主席。Ryan女士于2012年创立了资本市场和传播公司Barbara Ryan Advisors，此前她在华尔街担任了30多年的卖方研究分析师，覆盖美国大盘制药行业。Ryan女士在广泛的生命科学公司的股权和债务融资、并购、估值、SEC报告、财务分析和公司战略方面拥有丰富的经验。Ryan女士参与了几笔业内最大的并购交易；Shire对艾伯维恶意收购企图的辩护、Shire对Baxalta的收购、Allergan对Valeant的辩护以及培瑞克对Mylan的辩护。Ryan女士于2014年1月至2017年12月期间担任Radius Health的执行团队成员和披露委员会成员，在该公司的首次公开募股和随后的后续发行中发挥了关键作用，该公司筹集了超过10亿美元。此前，Ryan女士曾在德意志银行/Alex Brown担任董事总经理并担任该公司医药研究团队负责人长达19年，并于1982年在贝尔斯登开始了她覆盖医药行业的研究生涯。Ryan女士还覆盖了药物批发商和PBM，并且是包括Express Scripts、PSSI和亨利香恩服务在内的许多备受瞩目的IPO的首席分析师。Ryan女士目前在Indivior Pharmaceuticals，Inc.担任董事会董事，她在该公司担任薪酬委员会主席，在MiNK Therapeutics Therapeutics，她在该公司担任审计委员会主席，Safecor Health和Azitra Inc.以及非营利组织Red Door Community（前身为Gilda's Club NYC）担任董事会董事。Ryan女士是Fabulous Pharma Females的创始人，这是一家非营利组织，其使命是在生物制药行业推动女性发展，是《制药高管》杂志编辑顾问委员会成员，也是GLG研究所的教员。
- Barbara Ryan has been a member of Invo Fertility, Inc.'s Board, a member of the Audit Committee and Nominating and Governance Committee since September 2020 and the Chairwoman of the Compensation Committee since May 2024. Ms. Ryan founded Barbara Ryan Advisors, a capital markets and communications firm, in 2012 following a more than 30 year career on Wall Street as a sell side research analyst covering the US Large Cap Pharmaceutical Industry. Ms. Ryan has deep experience in equity and debt financings, M&A, valuation, SEC reporting, financial analysis and corporate strategy across a broad range of life sciences companies. Ms. Ryan worked on several of the industry's largest M&A transactions; Shire's defense versus a hostile takeover attempt by Abbvie, Shire's takeover of Baxalta, Allergan's defense against Valeant and Perrigo's defense versus Mylan. Ms. Ryan served as an executive team member and on the disclosure committee for Radius Health from January 2014 to December 2017 and played a critical role in the company's IPO and subsequent follow on offerings which raised over $1 billion. Previously, Ms. Ryan was a Managing Director at Deutsche Bank/Alex Brown and Head of the company's Pharmaceutical Research Team for 19 years and began her research career covering the pharmaceutical industry at Bear Stearns in 1982. Ms. Ryan also covered the drug wholesalers and PBMs and was the lead analyst on many high profile IPO's including Express Scripts, PSSI, and Henry Schein. Ms. Ryan currently serves as a director on the Board of Indivior Pharmaceuticals, Inc. where she Chairs the Compensation Committee, MiNK Therapeutics where she Chairs the Audit Committee, Safecor Health, and Azitra Inc. as well as The Red Door Community (formerly Gilda's Club NYC), a non profit organization. Ms. Ryan is the Founder of Fabulous Pharma Females, a non profit whose mission is to advance women in the biopharma industry, is a member of the Editorial Advisory Board of Pharmaceutical Executive Magazine, and a Faculty member of the GLG Institute.
- Peter Behner
-
Peter Behner自2021年4月起担任我们的董事会成员。自2020年7月以来，Behner先生一直担任安永会计师事务所的全球健康科学与健康战略和交易负责人。Behner先生于2018年9月加入安永会计师事务所，担任制药和生命科学行业的全球交易服务负责人。从2013年到2018年6月，Behner先生担任欧洲医疗行业负责人，并担任欧洲，中东和非洲地区Strategy&PricewaterhouseCoopers PwC公司的制药与生命科学行业的咨询负责人。从2005年到2013年被PwC收购，Behner先生是Booz&Company的股权合伙人，与Booz Allen Hamilton一起，在BC从BAH分拆出来之前。从2003年到2005年，他曾担任A.T.Kearney公司的德国部门的合伙人，以及A.T.Kearney公司的欧洲制药和生命科学产业集团的负责人（从2004年到2005年）。此外，自2015年4月以来，Behner先生一直担任Rottendorf GmbH（一家制药合同开发和制造公司）的负责人。他拥有德国亚琛工业大学机械工程的BE&ME综合学位。
Peter Behner,held equity partnership positions for 18 years at a number of global strategy and management consulting firms prior to retiring from full time employment in September 2021. Since July 2020, Mr. Behner has served as Global Health Sciences & Wellness Strategy and Transactions Leader at Ernst & Young. Mr. Behner joined Ernst & Young in September 2018 as the Global Transaction Services Leader for the Pharmaceutical and Life Sciences Industries. From 2013 to June 2018 Mr. Behner was European Head of Health Industries and Consulting Leader for the Pharma & Life Sciences Industries for the EMEA region for Strategy&, a PricewaterhouseCoopers ("PwC") company. From 2005 until its 2013 acquisition by PwC, Mr. Behner was an equity partner at Booz & Company ("BC"), together with Booz Allen Hamilton ("BAH") prior to BC's spin-out from BAH. From 2003 to 2005 Mr. Behner was a partner at A.T. Kearney in its German Division, and from 2004 to 2005 he was Head of A.T. Kearney's European Pharmaceutical and Life Science Industry group. Additionally, between April 2015 until August of 2021, Mr. Behner served as a Principal of Rottendorf GmbH, a German-based global pharmaceutical contract development and manufacturing company. Mr. Behner currently works part-time as a non-equity based Operating Partner at Armira Partners GmbH, a German private equity firm as Managing Director of BEMA1 GmbH, a Germany-based real estate investment firm. He holds a combined BE & ME degree in Mechanical Engineering for RWTH Aachen University in Germany. - Peter Behner自2021年4月起担任我们的董事会成员。自2020年7月以来，Behner先生一直担任安永会计师事务所的全球健康科学与健康战略和交易负责人。Behner先生于2018年9月加入安永会计师事务所，担任制药和生命科学行业的全球交易服务负责人。从2013年到2018年6月，Behner先生担任欧洲医疗行业负责人，并担任欧洲，中东和非洲地区Strategy&PricewaterhouseCoopers PwC公司的制药与生命科学行业的咨询负责人。从2005年到2013年被PwC收购，Behner先生是Booz&Company的股权合伙人，与Booz Allen Hamilton一起，在BC从BAH分拆出来之前。从2003年到2005年，他曾担任A.T.Kearney公司的德国部门的合伙人，以及A.T.Kearney公司的欧洲制药和生命科学产业集团的负责人（从2004年到2005年）。此外，自2015年4月以来，Behner先生一直担任Rottendorf GmbH（一家制药合同开发和制造公司）的负责人。他拥有德国亚琛工业大学机械工程的BE&ME综合学位。
- Peter Behner,held equity partnership positions for 18 years at a number of global strategy and management consulting firms prior to retiring from full time employment in September 2021. Since July 2020, Mr. Behner has served as Global Health Sciences & Wellness Strategy and Transactions Leader at Ernst & Young. Mr. Behner joined Ernst & Young in September 2018 as the Global Transaction Services Leader for the Pharmaceutical and Life Sciences Industries. From 2013 to June 2018 Mr. Behner was European Head of Health Industries and Consulting Leader for the Pharma & Life Sciences Industries for the EMEA region for Strategy&, a PricewaterhouseCoopers ("PwC") company. From 2005 until its 2013 acquisition by PwC, Mr. Behner was an equity partner at Booz & Company ("BC"), together with Booz Allen Hamilton ("BAH") prior to BC's spin-out from BAH. From 2003 to 2005 Mr. Behner was a partner at A.T. Kearney in its German Division, and from 2004 to 2005 he was Head of A.T. Kearney's European Pharmaceutical and Life Science Industry group. Additionally, between April 2015 until August of 2021, Mr. Behner served as a Principal of Rottendorf GmbH, a German-based global pharmaceutical contract development and manufacturing company. Mr. Behner currently works part-time as a non-equity based Operating Partner at Armira Partners GmbH, a German private equity firm as Managing Director of BEMA1 GmbH, a Germany-based real estate investment firm. He holds a combined BE & ME degree in Mechanical Engineering for RWTH Aachen University in Germany.
- John Holcomb
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Garo H. Armen
-
Garo H. Armen是Protagenic治疗公司的创始人之一，于2004年9月加入Protagenic治疗公司。Garo H. Armen是Agenus Inc.的董事长兼首席执行官，他在1994年与他人共同创立了一家生物技术公司。从2002年中到2004年，他还担任了成功重组的生物制药公司Elan Corporation，plc的董事会主席。在加入Agenus Inc.之前，Armen博士创立了Armen Partners，这是一家专门从事生物技术和制药公司业务的资金管理公司，并且是1993年创立Immunex Lederle肿瘤学公司这一广为人知的项目的设计者。在更早之前，他是Dean Witter Reynolds研究部高级副总裁，他的职业生涯始于华尔街，在EF Hutton担任分析师和投资银行家。2002年，Armen博士创立了亚美尼亚儿童基金会，这是一个非营利组织，致力于大力重建和振兴贫困的亚美尼亚农村城镇，为儿童和青年提供直接和可持续的利益。由于他的人道主义努力，他于2004年获得埃利斯岛荣誉勋章；由于他在生物技术和医学研究方面取得的成就，他于2006年获得萨宾疫苗研究所颁发的萨宾人道主义奖。Armen博士也是安永会计师事务所2002年纽约市年度生物技术企业家，并于2005年获得黑素瘤研究基金会颁发的希望之翼奖，以表彰他对黑素瘤社区的持续承诺。Armen博士在纽约城市大学研究生中心获得物理化学博士学位，之后他在纽约长岛的Brookhaven国家实验室担任研究员。
Garo H. Armen,oversaw the successful restructuring of the biopharmaceutical company Elan Corporation, plc, where he served as Chairman of the Board of Directors. Dr. Armen began his research career at Brookhaven National Laboratory subsequent to which he made a transition to Wall Street, as an analyst and investment banker at EF Hutton and then at Dean Witter Reynolds (now Morgan Stanley). Dr. Armen received his PhD in physical chemistry from the City University of New York. - Garo H. Armen是Protagenic治疗公司的创始人之一，于2004年9月加入Protagenic治疗公司。Garo H. Armen是Agenus Inc.的董事长兼首席执行官，他在1994年与他人共同创立了一家生物技术公司。从2002年中到2004年，他还担任了成功重组的生物制药公司Elan Corporation，plc的董事会主席。在加入Agenus Inc.之前，Armen博士创立了Armen Partners，这是一家专门从事生物技术和制药公司业务的资金管理公司，并且是1993年创立Immunex Lederle肿瘤学公司这一广为人知的项目的设计者。在更早之前，他是Dean Witter Reynolds研究部高级副总裁，他的职业生涯始于华尔街，在EF Hutton担任分析师和投资银行家。2002年，Armen博士创立了亚美尼亚儿童基金会，这是一个非营利组织，致力于大力重建和振兴贫困的亚美尼亚农村城镇，为儿童和青年提供直接和可持续的利益。由于他的人道主义努力，他于2004年获得埃利斯岛荣誉勋章；由于他在生物技术和医学研究方面取得的成就，他于2006年获得萨宾疫苗研究所颁发的萨宾人道主义奖。Armen博士也是安永会计师事务所2002年纽约市年度生物技术企业家，并于2005年获得黑素瘤研究基金会颁发的希望之翼奖，以表彰他对黑素瘤社区的持续承诺。Armen博士在纽约城市大学研究生中心获得物理化学博士学位，之后他在纽约长岛的Brookhaven国家实验室担任研究员。
- Garo H. Armen,oversaw the successful restructuring of the biopharmaceutical company Elan Corporation, plc, where he served as Chairman of the Board of Directors. Dr. Armen began his research career at Brookhaven National Laboratory subsequent to which he made a transition to Wall Street, as an analyst and investment banker at EF Hutton and then at Dean Witter Reynolds (now Morgan Stanley). Dr. Armen received his PhD in physical chemistry from the City University of New York.
- Brian Corvese
-
Brian Corvese，自1999年以来，他一直担任Vencor Capital（一家在中东和地中海地区进行电信和技术投资的私募股权公司）的总裁和创始人。在Vencor工作之前，他曾担任索罗斯基金管理公司（当时世界上最大的对冲基金）的董事总经理和合伙人，从事美国和全球股票市场的投资。从1988年到1996年，他是Chancellor Capital Management（一家250亿美元的资金管理公司）的合伙人。在Chancellor任职期间，他曾担任投资组合经理，负责基础行业、重组、特殊情况、公司治理投资的投资，以及创立和管理自己的对冲基金。从1981年到1988年，Corvese先生在Drexel Burnham Lambert（“Drexel”）担任股票分析师，跟踪化学和特种化学行业，并参与了大量的并购活动。在Drexel任职期间，他是机构投资者（Institutional Investor）排名的顶级化学和特种化学研究团队的成员。他目前担任MiNK Therapeutics， Inc.（位于埃及开罗的国家电信公司）和Protagenic Therapeutics （Agenus的子公司，位于加拿大安大略省）的董事会成员。他获得Rhode Island大学的金融和政治学学位，并就读于纽约大学研究生院。
Brian Corvese,worked on investments in the U.S. and global equity markets as a Managing Director and partner at Soros Fund Management, the largest hedge fund in the world at the time. From 1988 to 1996, Mr. Corvese was a partner at Chancellor Capital Management ("Chancellor"), a $25 billion money management firm. While at Chancellor, Mr. Corvese was a Portfolio Manager with responsibility for investments made in basic industries, restructurings, and special situations, corporate governance investments, as well as founded and managed his own hedge fund. From 1981 to 1988, Mr. Corvese was with Drexel Burnham Lambert ("Drexel") as an equity analyst following the chemical and specialty chemical industries and participated in a significant number of merger and acquisition activities. While at Drexel, Mr. Corvese was a member of the top chemical and specialty chemical research team, as ranked by Institutional Investor. Mr. Corvese currently serves on the Board of Directors of MiNK Therapeutics, Inc., the National Telecommunications Corporation, based in Cairo, Egypt, and Protagenic Therapeutics, an affiliate of Agenus, based in Ontario, Canada. Mr. Corvese earned degrees in finance and political science from The University of Rhode Island and attended New York University Graduate School. - Brian Corvese，自1999年以来，他一直担任Vencor Capital（一家在中东和地中海地区进行电信和技术投资的私募股权公司）的总裁和创始人。在Vencor工作之前，他曾担任索罗斯基金管理公司（当时世界上最大的对冲基金）的董事总经理和合伙人，从事美国和全球股票市场的投资。从1988年到1996年，他是Chancellor Capital Management（一家250亿美元的资金管理公司）的合伙人。在Chancellor任职期间，他曾担任投资组合经理，负责基础行业、重组、特殊情况、公司治理投资的投资，以及创立和管理自己的对冲基金。从1981年到1988年，Corvese先生在Drexel Burnham Lambert（“Drexel”）担任股票分析师，跟踪化学和特种化学行业，并参与了大量的并购活动。在Drexel任职期间，他是机构投资者（Institutional Investor）排名的顶级化学和特种化学研究团队的成员。他目前担任MiNK Therapeutics， Inc.（位于埃及开罗的国家电信公司）和Protagenic Therapeutics （Agenus的子公司，位于加拿大安大略省）的董事会成员。他获得Rhode Island大学的金融和政治学学位，并就读于纽约大学研究生院。
- Brian Corvese,worked on investments in the U.S. and global equity markets as a Managing Director and partner at Soros Fund Management, the largest hedge fund in the world at the time. From 1988 to 1996, Mr. Corvese was a partner at Chancellor Capital Management ("Chancellor"), a $25 billion money management firm. While at Chancellor, Mr. Corvese was a Portfolio Manager with responsibility for investments made in basic industries, restructurings, and special situations, corporate governance investments, as well as founded and managed his own hedge fund. From 1981 to 1988, Mr. Corvese was with Drexel Burnham Lambert ("Drexel") as an equity analyst following the chemical and specialty chemical industries and participated in a significant number of merger and acquisition activities. While at Drexel, Mr. Corvese was a member of the top chemical and specialty chemical research team, as ranked by Institutional Investor. Mr. Corvese currently serves on the Board of Directors of MiNK Therapeutics, Inc., the National Telecommunications Corporation, based in Cairo, Egypt, and Protagenic Therapeutics, an affiliate of Agenus, based in Ontario, Canada. Mr. Corvese earned degrees in finance and political science from The University of Rhode Island and attended New York University Graduate School.
高管简历
中英对照 | 中文 | 英文- Jennifer S. Buell
Jennifer S.Buell自2018年以来一直担任我们的首席运营官，并于2019年12月成为我们的总裁。2013年11月至2016年7月，Buell博士担任该公司的Vice President、研究与开发运营和项目管理。2016年7月至2017年11月，她担任公司Vice President、研究和对外事务，2017年11月至2018年11月，她担任首席通信和对外事务官。Buell博士在塔夫茨大学（Tufts University）获得细胞、生化和分子生物化学博士学位，并获得生物统计学硕士学位。
Jennifer S. Buell,has been President and CEO of MiNK Therapeutics, Inc. (subsidiary of Agenus) and since 2023 the Chairman, Executive Council at Agenus. From 2018 to 2021, Dr. Buell was President and Chief Operating Officer at Agenus, where she was responsible for organizational operations, investor relations and external affairs. Prior to Agenus, Dr. Buell held leadership positions in R&D operations at Bristol-Myers Squibb and Harvard Clinical Research Institute (Baim), where she was involved in the development strategy and operations for a portfolio of industry and government-sponsored clinical programs. She obtained her Ph.D. in Cellular, Biochemical, and Molecular Biochemistry with an M.S. in Biostatistics from Tufts University.- Jennifer S.Buell自2018年以来一直担任我们的首席运营官，并于2019年12月成为我们的总裁。2013年11月至2016年7月，Buell博士担任该公司的Vice President、研究与开发运营和项目管理。2016年7月至2017年11月，她担任公司Vice President、研究和对外事务，2017年11月至2018年11月，她担任首席通信和对外事务官。Buell博士在塔夫茨大学（Tufts University）获得细胞、生化和分子生物化学博士学位，并获得生物统计学硕士学位。
- Jennifer S. Buell,has been President and CEO of MiNK Therapeutics, Inc. (subsidiary of Agenus) and since 2023 the Chairman, Executive Council at Agenus. From 2018 to 2021, Dr. Buell was President and Chief Operating Officer at Agenus, where she was responsible for organizational operations, investor relations and external affairs. Prior to Agenus, Dr. Buell held leadership positions in R&D operations at Bristol-Myers Squibb and Harvard Clinical Research Institute (Baim), where she was involved in the development strategy and operations for a portfolio of industry and government-sponsored clinical programs. She obtained her Ph.D. in Cellular, Biochemical, and Molecular Biochemistry with an M.S. in Biostatistics from Tufts University.
- Christine M. Klaskin
Christine M. Klaskin，自2012年起担任董事会的成员。自2006年以来，她是Agenus公司（纳斯达克交易代码：AGEN）的财务副总裁，一家开发和商业化技术来治疗癌症和传染性疾病的生物技术公司。克拉斯女士在1996年加入Agenus公司，并担任各种财务职位。从1987年到1996年，她任职于安达信会计师事务所，最近担任审计经理。克拉斯女士获得乔治华盛顿大学的会计学学士学位。
Christine M. Klaskin,has held various positions within the finance department and has been involved in all equity and debt offerings of the Company including its IPO. Additionally, Ms. Klaskin serves as the Treasurer of MiNK Therapeutics, Inc. Prior to joining Agenus, Ms. Klaskin was employed by Arthur Andersen as an audit manager. Ms. Klaskin received her Bachelor of Accountancy from The George Washington University.- Christine M. Klaskin，自2012年起担任董事会的成员。自2006年以来，她是Agenus公司（纳斯达克交易代码：AGEN）的财务副总裁，一家开发和商业化技术来治疗癌症和传染性疾病的生物技术公司。克拉斯女士在1996年加入Agenus公司，并担任各种财务职位。从1987年到1996年，她任职于安达信会计师事务所，最近担任审计经理。克拉斯女士获得乔治华盛顿大学的会计学学士学位。
- Christine M. Klaskin,has held various positions within the finance department and has been involved in all equity and debt offerings of the Company including its IPO. Additionally, Ms. Klaskin serves as the Treasurer of MiNK Therapeutics, Inc. Prior to joining Agenus, Ms. Klaskin was employed by Arthur Andersen as an audit manager. Ms. Klaskin received her Bachelor of Accountancy from The George Washington University.